Mikael Lönn

Director

BoardM

FI·FIN-FSA

Genovis AB Annexin Pharmaceuticals AB (publ)Annexin Pharmaceuticals AB (publ)

Cumul. flow

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Explore the full record of transactions filed by Mikael Lönn, Director. Insider active across 3 companies, notably Genovis AB. Cumulatively, 3 reports have been published. The latest transaction was disclosed on 22 May 2025 — Sale. Regulator: FIN-FSA. The full history is accessible without signup.

Declarations3 total

Executives●SaleGGenovis AB22FIN-FSA

M

Mikael LönnStyrelseledamot

€599,306255,653 shares@ €2.34420.044% mcap52.5% of flow

Aktie

FI:A003O854-1·22 May 2025

FIN-FSA ↗

Executives●PurchaseAAnnexin Pharmaceuticals AB (publ)28FIN-FSA

M

Mikael LönnStyrelseledamot

€1m43,251,795 shares@ €0.02741.12% mcap100.0% of flow

BTA (betald tecknad aktie)

FI:A003M856-1·24 Mar 2025

Ideal exit: 19 Dec 2025 (T+270)

FIN-FSA ↗

Executives●SaleGGenovis AB21FIN-FSA

M

Mikael LönnStyrelseledamot

€541,392235,000 shares@ €2.30380.040% mcap47.5% of flow

Aktie

FI:A003M263-1·5 Mar 2025

FIN-FSA ↗

3 of 3 declarations

About Mikael Lönn

Mikael Lönn is a Board Member of Genovis AB. He brings his expertise to the board, contributing to strategic decision-making for the company. His role is essential in ensuring good governance and sustainable development for Genovis.